References
- Kupper TS. Immunologic targets in psoriasis. N. Engl. J. Med.349, 1987–1990 (2003).
- Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in subjects with psoriasis. N. Engl. J. Med.349, 2014–2022 (2003).
- Papp KA, Trying S, Lahfa M et al. A global Phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br. J. Dermatol.152, 1304–1312 (2005).
- Gottlieb AB, Matheson RT, Lowe N et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch. Dermatol.139, 1627–1632 (2003).
- Moore A, Gordon KB, Kang S et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J. Am. Acad. Dermatol.56, 598–603 (2007).
- Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann. Rheum. Dis.64(Suppl. 2), 69–73 (2005).
- Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician’s Global Assessment. J. Am. Acad. Dermatol.51, 563–569 (2004).
- van de Kerkhof P, Segaert S, Lahfa M et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis. Br. J. Dermatol.159, 1177–1185 (2008).